Eczema Treatment Results & Relief with Adbry® | Adbry®

Approved for adults and children ages 12+ years. Click here for different pediatric dosing information.

Eczema relief with Adbry

It can be frustrating when your is still not under control. Adbry® (tralokinumab-ldrm) works inside the body to help get clearer skin and control the unbearable itch for the long-term. Adbry was used in 2 clinical trials for up to 1 year, and 1 trial for up to 8 months. Talk to your healthcare professional to see if Adbry is right for you.

Clearer skin

Adbry helped visibly improve the look and texture of skin at 4 months.

See the results

Image of woman’s back

Not an actual patient.
Individual results may vary.

Image of woman looking over shoulder

Not an actual patient.
Individual results may vary.

Itch less

Adults using Adbry experienced significantly less itch.

See the results

Maintained results

In all 3 clinical trials where adults used Adbry every other week, more patients experienced relief at 4 months, and maintained relief through the end of the trials, either at 8 months or 12 months.

Image of man with the words "eczema relief" on his arm

Not an actual patient. Individual results may vary.

How was Adbry studied in clinical trials?

Adbry was studied in 3 separate clinical trials of almost 2,000 adults aged 18 and older with moderate-to-severe (). People in the trials injected 2 prefilled syringes every other week.

TRIAL 1: 601 people used Adbry; 197 used

TRIAL 2: 577 people used Adbry; 193 used

TRIAL 3: 243 people used Adbry + ; 123 used +

Clearer skin was measured in 2 ways:

The percentage of people who saw CLEAR OR ALMOST CLEAR SKIN
The percentage of people who saw a 75% OR BETTER IMPROVEMENT IN SKIN

Collapse

Expand

Clearer skin and less itch

243 people used Adbry every other week + as needed; 123 people used every other week + as needed.

Clear or almost clear skin

Graphic of trial results showing at 4 months almost 40% of people vs 27% using placebo saw clear or almost clear skin. At 8 months 89% of people maintained clear or almost clear skin.

75% or better improvement in skin

Graphic of trial results showing at 4 months 56% of people vs 37% using placebo saw 75% or better improvement in skin. At 8 months 92% maintained a 75% or better improvement in skin.

Additional results

Icon of itching

After 4 months, almost 50% of people experienced significantly less itch (vs 35% of people using ).

Collapse

Expand

Clearer skin and less itch

601 people used Adbry every other week; 197 used every other week.

At 4 months of Adbry alone:

16% of people saw CLEAR OR ALMOST CLEAR SKIN (vs 7% of people using )
25% of people saw a 75% OR BETTER IMPROVEMENT IN SKIN (vs 13% of people using )

Icon of itching

20% of people experienced less itch (vs 10% of people using ).

At 1 year of Adbry alone:

Graphic of trial results showing 51% of people maintained clear or almost clear skin at 1 year.

Graphic of trial results showing 60% of people maintained a 75% or better improvement in skin at 1 year.

Collapse

Expand

Clearer skin and less itch

577 people used Adbry every other week; 193 used every other week.

At 4 months of Adbry alone:

21% of people saw CLEAR OR ALMOST CLEAR SKIN (vs 9% of people using )
33% of people saw a 75% OR BETTER IMPROVEMENT IN SKIN (vs 10% of people using )

Icon of itching

25% of people experienced less itch (vs 9% of people using ).

At 1 year of Adbry alone:

Graphic of trial results showing 60% of people maintained clear or almost clear skin at 1 year.

Graphic of trial results showing 57 % of people maintained a 75% or better improvement in skin at 1 year.

Not an actual patient.
Individual results may vary.

Across Trials 1, 2, and 3, more people using Adbry saw a 90% or better improvement in their skin compared to those using .

Keep learning about Adbry:

Adbry side effects

See the safety information

How to use Adbry

Watch the video

Frequently asked questions

Get Adbry answers

INDICATION AND IMPORTANT SAFETY INFORMATION

Read more Collapse

What is ADBRY?

ADBRY® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ADBRY can be used with or without topical corticosteroids.
It is not known if ADBRY is safe and effective in children under 12 years of age.

Do not use ADBRY if you are allergic to tralokinumab or to any of its ingredients.

What should I discuss with my healthcare provider before starting ADBRY?

Tell your healthcare provider about all your medical conditions, including if you:

have eye problems.
have a parasitic (helminth) infection.
are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with ADBRY.
are pregnant or plan to become pregnant. It is not known whether ADBRY will harm your unborn baby. There is a pregnancy exposure registry for women who use ADBRY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. You or your healthcare provider can get information and enroll you in this registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/.
are breastfeeding or plan to breastfeed. It is not known whether ADBRY passes into your breast milk and if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use ADBRY?

See the detailed “Instructions for Use” that comes with ADBRY for information on how to prepare and inject ADBRY and how to properly store and throw away (dispose of) used ADBRY prefilled syringes.
Use ADBRY exactly as prescribed by your healthcare provider.
Your healthcare provider will tell you how much ADBRY to inject and when to inject it.
ADBRY comes as a single-dose (150 mg) prefilled syringe with needle guard.
ADBRY is given as an injection under the skin (subcutaneous injection).
If your healthcare provider decides that you or a caregiver can give the injection of ADBRY, you or your caregiver should receive training on the right way to prepare and inject ADBRY. Do not try to inject ADBRY until you have been shown the right way by your healthcare provider.
If you miss a dose, inject the missed dose as soon as possible, then continue with your next dose at your regular scheduled time.
If you inject too much ADBRY than prescribed, call your healthcare provider or call Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Your healthcare provider may prescribe other medicines to use with ADBRY. Use the other prescribed medicines exactly as your healthcare provider tells you to.

What are the possible side effects of ADBRY?

ADBRY can cause serious side effects including:

Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:
- breathing problems
- itching
- skin rash
- swelling of the face, mouth, and tongue
- fainting, dizziness, feeling lightheaded (low blood pressure)
- hives

Eye problems. Tell your healthcare provider if you have any worsening eye problems, including eye pain or changes in vision.

The most common side effects of ADBRY include:

Upper respiratory tract infections
Eye and eyelid inflammation, including redness, swelling, and itching
Injection site reactions
High count of a certain white blood cell (eosinophilia)

These are not all of the possible side effects of ADBRY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information and Instructions for Use.